jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Pharmacy PracticeNOW IN
Article

Pharmaceutical services in a Mexican pain relief and palliative care institute

Raymundo Escutia Gutiérrez1, César R. Cortéz Álvarez2, Rosa Margarita Álvarez Álvarez3, Jorge LV. Flores Hernández4, Jéssica Gutiérrez Godínez5, José G. López y López6

  1. 1Director of the Jalisco Pain Relief, and Palliative Care Institute (Palia Institute), Secretary of Health, Government of Jalisco, Mexico.
  2. 2Coordinator of Pharmacy, Faculty of Exact Sciences and Engineering, University de Guadalajara, Mexico.
  3. 3Director of the Jalisco Pain Relief, and Palliative Care Institute, Secretary of Health, Government of Jalisco, Mexico.
  4. 4Physiology Institute, Autonomous University of Puebla, Mexico.
  5. 5Professor and Coordinator of the Pharmaceutical Services Office, Autonomous University of Puebla, Mexico.
  6. 6Professor and Director of the Pharmaceutical Services Office, Faculty of Chemical Sciences, Autonomous University of Puebla, Mexico.

Volume 5, Issue 4 · pp. 174–178 · PUBLISHED 2007 · DOI:

View on PP original site ↗

ABSTRACT

Neither the purchase nor the distribution of pharmaceuticals in hospitals and community pharmacies in Mexico is under the care of pharmacists. Some are under control of physicians. This report presents the results of the implementation of some pharmaceutical services for the Jalisco Pain Relief, and Palliative Care Institute (Palia Institute), under the direction of the Secretary of Health, Government of Jalisco. The services implemented were drug distribution system, Drug Information Service, Pharmacovigilance Program, and home pharmacotherapy follow-up pilot program for patients with advanced illness, with the ultimate goal of using the appropriate medication. The drug distribution system included dispensing of opioid pain medications, antidepressants, anticonvulsants, NSAIDs, anxiolytic drugs, steroid drugs, laxatives, and anti-emetics. The frequently used drugs were morphine sulfate (62%), amitriptyline (6.4%), and dextropropoxyphene (5.8%). The Drug Information Service answered 114 consultations, mainly asked by a physician (71%) concerned with adverse drug reactions and contraindications (21%). The pharmacovigilance program identified 146 suspected adverse drug reactions and classified them reasonably as possible (27%), probable (69%), and certain (4%). These were attributed mainly to pregabalin and tramadol. The home pharmacotherapy follow-up pilot program cared for patients with different cancer diagnoses and drug-related problems (DRP), which were identified and classified (according to second Granada Consensus) for pharmaceutical intervention as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%), DRP 5 (24%), or DRP 6 (28%). This report provides information concerning the accurate use of medication and, above all, an opportunity for Mexican pharmacists to become a part of health teams seeking to resolve drug-related problems.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Gutiérrez, R. E., Álvarez, C. R. C., Álvarez, R. M. Á., Hernández, J. L. F., Godínez, J. G., & López, J. G. L. Y. (2007). Pharmaceutical services in a Mexican pain relief and palliative care institute. Pharmacy Practice, 5(4), 174–178.